SCHEMBL719533

SCHEMBL719533

Cc1c(C(Cl)C2CCCCC2)oc2cc(F)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAOB P27338 6/20 0.35
ACHE P22303 4/20 0.33
HSD17B3 P37058 1/20 0.33
NR1H2 P55055 1/20 0.33
MAOA P21397 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
SLC6A4 P31645 1/20 0.32
MCHR1 Q99705 3/20 0.32
ATM Q13315 1/20 0.31
KCNH2 Q12809 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718379 0.90 NPC1 (0.52) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL721039 0.84 NPC1 (0.44) NPC1RAB9AMAOBACHEHSD17B3
SCHEMBL716824 0.81 NPC1 (0.48) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL721579 0.78 NPC1 (0.41) NPC1RAB9AKMT2AALDH1A1KCNH2
SCHEMBL721218 0.77 MCL1 (0.43) NPC1RAB9AALDH1A1KCNH2
SCHEMBL718939 0.74 RAB9A (0.54) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL718925 0.74 NPC1 (0.55) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL721329 0.73 HRH4 (0.36) NPC1RAB9AMAOBMAOAALDH1A1
SCHEMBL718548 0.72 RAB9A (0.53) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL9216296 0.66 MAOB (0.47) MAOBACHEHSD17B3POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885MAOB 2146/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885MAOB 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.